



Systematic or Meta-analysis Studies

Retreatment with anti-EGFR monoclonal antibodies in metastatic colorectal cancer: Systematic review of different strategies



Gianluca Mauri^{a,b,1}, Elio Gregory Pizzuttilo^{a,b,1}, Alessio Amatu^a, Katia Bencardino^a, Laura Palmeri^a, Erica Francesca Bonazzina^a, Federica Tosi^a, Giulia Carlo Stella^a, Giovanni Burrafato^a, Francesco Scaglione^{a,b}, Silvia Marsoni^{a,e}, Giulia Siravegna^{c,d}, Alberto Bardelli^{c,d}, Salvatore Siena^{a,b}, Andrea Sartore-Bianchi^{a,b,*}

^a Niguarda Cancer Center, Grande Ospedale Metropolitano Niguarda, Milan, Italy

^b Università degli Studi di Milano, Dipartimento di Oncologia ed Emato-Oncologia, Milano, Italy

^c Candiolo Cancer Institute – FPO, IRCCS, Candiolo, Turin, Italy

^d Department of Oncology, University of Torino, Candiolo, Turin, Italy

^e FIRC Institute of Molecular Oncology (IFOM), Milan, Italy

ARTICLE INFO

Keywords:

Colorectal cancer
Anti-EGFR rechallenge
Anti-EGFR monoclonal antibodies
Liquid biopsy
Panitumumab
Cetuximab

ABSTRACT

Background: Despite advances in precision oncology and immunotherapy of tumors, little progress has been made in metastatic colorectal cancer (mCRC) in recent years. Therefore, making the most of available therapies is a necessity. Several studies, based on the pulsatile behavior of RAS clones under EGFR blockade, investigated whether readministration of EGFR-targeted agents is effective beyond second line.

Methods: A systematic review of studies of retreatment with anti-EGFR monoclonal antibodies has been performed from January 2005 to December 2018 according to PRISMA criteria from PubMed, ESMO and ASCO meetings libraries and Clinicaltrial.gov. Efficacy has been evaluated as objective response rate and survival in available publications. In addition, type and incidence of side effects occurring during on anti-EGFR retreatment have been considered.

Results: 26 publications have been retrieved, of which 20 full-text articles and 6 abstracts and categorized as for the retreatment strategy into five groups: rechallenge (n = 10), reintroduction (n = 4), sequence (n = 5), dose escalation (n = 1) and mixed (n = 6). Data of efficacy displayed high heterogeneity across different strategies (objective response rate, ORR = 0.0–53.8%; disease control rate, DCR = 24.0–89.7%), with best results in the setting of rechallenge (ORR = 2.9–53.8%; DCR = 40.0–89.7%).

Conclusions: Rechallenge with anti-EGFR provides clinical benefit in molecularly selected mCRC patients beyond second line. Further ctDNA-guided studies comparing this option of treatment with current approved advanced line treatments are warranted.

Introduction

Colorectal cancer (CRC) is the second most commonly diagnosed cancer worldwide, causing every year more than 1,500,000 deaths worldwide [1,2]. Overall survival (OS) after 5 years from diagnosis of CRC is 60% [3]. Median OS for patients with metastatic CRC (mCRC) is up to 30 months and more than double if compared to 20 years ago [3–7]. However, despite advances in precision oncology and immunotherapy of tumors, little progress has been made in mCRC in more

recent years. Therefore, making the most of available therapies is a necessity.

Molecularly targeted agents offered more therapeutic options improving both progression-free survival (PFS) and OS of mCRC patients [6]. As reported by the most recent European Society for Medical Oncology (ESMO) Clinical Practice Guidelines and by the National Comprehensive Cancer Network (NCCN) for treatment of mCRC, several biological targeted agents are recommended for first-line and second-line treatments in combination with FOLFOX, FOLFIRI or FOLFOXIRI

* Corresponding author at: Dipartimento di Oncologia ed Emato-Oncologia, Università degli Studi di Milano, Grande Ospedale Metropolitano Niguarda, Piazza Ospedale Maggiore, 3, 20162 Milan, Italy.

E-mail address: andrea.sartorebianchi@unimi.it (A. Sartore-Bianchi).

¹ G. Mauri and E.G. Pizzuttilo contributed equally as first authors.

[8,9]. The anti-Vascular Endothelial Growth Factor (VEGF) bevacizumab, or the anti-Epidermal Growth Factor Receptor (EGFR) cetuximab or panitumumab are approved in first as well as in second line treatment [8]. In further lines, treatment options are still limited [10]. The multi-tyrosine kinase inhibitor regorafenib and trifluridine/tipiracil are recommended after standard cytotoxic and targeted treatments, both leading to a modest incremental survival advantage that should be weighed against toxicity concerns [8,10–12]. In third-line/salvage therapy setting, in *RAS* wild-type patients not previously treated with anti-EGFR antibodies, cetuximab in combination with irinotecan or panitumumab monotherapy should be considered [8,13,14]. Beyond third line treatment, the best choice is represented by clinical trials enrollment.

There are well known molecular criteria to select patients more likely to benefit from anti-EGFR targeted treatment. *KRAS* mutations occurring in exon 2, both in codons 12 and 13, are reported in up to 35%–45% of mCRC and they are negative predictive biomarkers for cetuximab or panitumumab efficacy [6,15,16]. An additional 14–20% of tumors are characterized by oncogenic mutations in *KRAS* exons 3 and 4 and *NRAS* exons 2, 3 and 4 [17,18]. The full spectrum of *KRAS* and *NRAS* mutations (“all-*RAS*”) must be analyzed to identify patients who will benefit from treatment based on anti-EGFR antibodies [6,8,9]. Several retrospective studies showed that also *BRAF* V600E and *PIK3CA* exon 20 mutations, together with *PTEN* loss, are negative predictive biomarkers for anti-EGFR monoclonal antibodies efficacy [19–21]. In particular, *BRAF* V600E mutation entails a limited benefit from anti-EGFR treatment [6,20,22]. In addition, gene alterations including mutations and amplifications in *ERBB2*, *EGFR*, *FGFR1*, *PDGFRA*, and *MAP2K1* have been described as additional potential mechanisms of primary or secondary resistance [23–27].

A major limitation to therapies with EGFR-targeted agents is the emergence of acquired (secondary) resistance [16,28]. This takes place through three main mechanisms: mutations in the antibody-binding site (such as the EGFR extracellular domain variants); activation of alternative pathways; or reactivation of downstream signalling (such as *KRAS* or *NRAS* mutations) [24,28–32]. While the latter confer resistance to both cetuximab and panitumumab and are often involved in primary as well as in secondary resistance, acquired point mutations occurring in the extracellular domain of *EGFR* such as S492R, G465R, G465E, V441D or V441G develop only under the selective pressure of anti-EGFR drugs and differentially impact on resistance to cetuximab or panitumumab [31–33]. Importantly, studies using liquid biopsy [34] for longitudinal monitoring have revealed that mutant *RAS* clones arise in blood during EGFR blockade and decline upon withdrawal of treatment [26], overall displaying a pulsatile behavior that can be clinically exploited by re-administering EGFR inhibitors after clearance of these biomarkers of resistance. In particular, *RAS* and *EGFR* mutant clones exponentially decay, with a cumulative half-life of 4.3 months [35].

Based on these data, with the aim of expanding therapeutic options in the context of the *continuum of care* of mCRC patients, several studies and case reports have reported data concerning retreatment with cetuximab or panitumumab in patients who previously displayed a partial response or durable stable disease to the same agents. Different strategies have been adopted in this setting (Fig. 1):

- **Rechallenge:** retreatment after an intervening treatment line or a time interval free of anti-EGFR (ideally > 6 months) in tumors that displayed initial sensitivity (partial response/durable stable disease) and then proved resistance while on treatment [36,37];
- **Reintroduction:** retreatment with an anti-EGFR agent or anti-EGFR-based regimen to which the tumor has not yet proved to be resistant: i.e. the progression of disease did not take place while on therapy and the drug or regimen was suspended due to avoid cumulative toxicities, side effects or patients request [38];
- **Sequence:** retreatment soon after a prior progression to a different anti-EGFR drugs (i.e. panitumumab following cetuximab

progression);

- **Dose intensification:** retreatment with higher doses of the same anti-EGFR drug in order to overcome acquired resistance to standard dose (i.g. higher saturation of target sites) [39,40].

While multiple evidences indicate that some efficacy does take place with retreatment with anti-EGFR drugs in mCRC, this option is still under clinical scrutiny and, because of the lack of phase 3 data, it is not included in clinical guidelines for the management of mCRC. In this article we systematically review available studies, case reports, abstracts and ongoing clinical trials on anti-EGFR retreatment by re-challenge, reintroduction or other strategies.

Methods

Definition of the outcome

The purpose of this systematic review is to analyze the efficacy of an anti-EGFR targeted retreatment in mCRC patients. We considered the percentage of objective response rate (RR), stable disease (SD) and disease control rate (DCR) for each of the currently available publications. Studies reporting outcome in terms of survival have been included as well. In addition, we further analyzed type and incidence of side effects occurring during anti-EGFR retreatment.

Data sources and search strategy

A systematic literature review was performed on 4 December 2018 according to PRISMA Criteria of 2009 (Fig. 2) [41,42]. We reviewed MEDLINE/PubMed, ASCO Meeting Library, ESMO library and ClinicalTrials.gov for citation or ongoing trials from January 2005 to December 2018. The search criteria were limited to human studies published in English language. The Medical Subject Headings terms used for the search in PubMed were (“((((rechallenge) OR (reintroduction) OR (retreatment) OR (readministration)) AND ((cetuximab) OR (panitumumab) OR (anti-egfr)))) OR intermittent panitumumab OR panitumumab after cetuximab OR intermittent cetuximab”). The Medical Subject Headings used for the search both in ASCO and ESMO Libraries were (panitumumab/cetuximab rechallenge), (panitumumab/cetuximab reintroduction), (panitumumab/cetuximab intermittent), (panitumumab/cetuximab retreatment) and (panitumumab/cetuximab readministration). The Medical Subject Headings terms used for the search in ClinicalTrials.gov were (“colorectal cancer” as *condition/disease*) and (“panitumumab OR cetuximab” as *other terms*).

Selection criteria

To be included in this review, a publication had to fulfill the following inclusion criteria: study performed in mCRC patients treated with anti-EGFR monoclonal antibodies after a previous anti-EGFR based therapy. We included studies, abstracts and case reports published starting from 2005. The exclusion criterium was: publications written in language other than English.

Article analysis

Among the articles included in the systematic review according to selection criteria, we performed a comparison on the endpoints of different studies taking into consideration treatment strategies, primary tumor sidedness, *RAS* molecular status, outcome according to Response Rate (RR), Stable Disease (SD) and Disease Control Rate (DCR) and treatment related toxicities.

Results

According to the PRISMA Statement Criteria 2009 [42], we




Fig. 1. Different strategies of retreatment with anti-EGFR antibodies. The lines under the figures represent hypothetical changes in tumor burden during different therapies. (A) Rechallenge: retreatment after an intervening treatment line without anti-EGFR or after a therapy vacation in tumors that displayed initial sensitivity. (B) Reintroduction: retreatment with an anti-EGFR agent to which the tumor has not yet proved to be resistant. (C) Sequence: retreatment soon after a prior progression to a different anti-EGFR drug (i.e. panitumumab following cetuximab). (D) Dose intensification: retreatment with higher doses of the same anti-EGFR drug in order to overcome acquired or primary resistance to standard dose.

identified 27 records through database searching and 16 additional records through other sources (i.e. online meeting library, Clinical-Trial.gov) (Fig. 2). A total of 43 records were therefore screened to be included in the systematic review. Seven records were excluded for the following reasons: 5 were review articles [36,43–46] and 2 studies

evaluated a combination of anti-EGFR with other targeted therapies [44,47]. As a result, 36 records were eligible and included in the systematic review: 26 publications, of which 20 full-text articles studies on anti-EGFR retreatment and 6 abstracts presented at international congresses, and 10 ongoing clinical trials (Table 1). Seven articles were




Fig. 2. Flow diagram representing the systematic review process performed according to PRISMA Statement [44].

reports describing 5 or less patients but due to small sample size we did not analyze percentages of RR, DCR and SD which may have altered overall interpretation of data. The remaining studies had a minimum of 13 up to 78 patients enrolled.

Table 1 displays studies included in the systematic review according to the retreatment strategies defined in Fig. 1 reporting the type of study, the drug sequence adopted, the number of patients, sidedness of colorectal tumor, *RAS* status and the specimen analyzed, the anti-EGFR free interval, and the outcome. 10 publications has been classified as “rechallenge” [26,48–56], 4 as “reintroduction” [57–60], 5 as “sequence” [61–65] and 1 as “dose intensification” [66]. Six more articles were included as “mixed strategy” [67–71], as in these studies different modalities were used in the same study (i.e. rechallenge and sequence) or the retreatment strategy was not clearly stated by the authors.

As a whole, the studies displayed high heterogeneity in terms of efficacy across different strategies (RR = 0.0–53.8%; DCR = 24.0–89.7%), with best results in the setting of rechallenge (RR = 2.9–53.8%; DCR = 40.0–89.7%).

Rechallenge

Among articles *in extenso* two prospective peer-reviewed studies could be defined rechallenge studies, since (*K*)*RAS* wild-type patients had to progress to a previous cetuximab-based regimen before cetuximab and irinotecan and following an intervening treatment, with a median anti-EGFR-free interval of 6 months [48,54]. RR was 53.8%, SD 35.9% and DCR 89.7% in the article by Santini and coworkers [48] and

RR was 21.4%, SD 32.1% and DCR 53.5% in the article by Cremolini et al. [48]. A statistically significant correlation between benefit from the first cetuximab administration and the rechallenge was noticed [48]. In the recent CRICKET study, *RAS* and *BRAF* wild-type status was required to be included in the study [54]. In addition to these trials, other two case reports have been published adopting a rechallenge strategy [26,51]. More recently, several abstracts on anti-EGFR rechallenge strategy have been presented at ASCO and ESMO International Congresses. Three of them used cetuximab combined with chemotherapy in the retreatment setting, after a prior cetuximab benefit, with a RR ranging between 8.3 and 13.3%, and DCR between 40 and 50% [49,50,56]. Siena and colleagues described survival data of panitumumab rechallenge combined or not with a cytotoxic agent after a prior response to panitumumab: in this study OS was available (14.2 months) but no data on RR were provided [53]. Tsuji and collaborators reported data from panitumumab rechallenge in combination with irinotecan after prior response to panitumumab with chemotherapy, showing a 50% of DCR with 8% of RR [52]. Interestingly, studies in this category provide clinical confirmation of the seminal finding that *RAS* clones, as determined by circulating tumor DNA (ctDNA), display a pulsatile behavior and decline after interruption of EGFR pharmacological blockade leading to renewed susceptibility at retreatment [26,54]. The CRICKET study retrospectively evaluated ctDNA at the moment of rechallenge and reported that all patients achieving a PR were *RAS* wild-type in the ctDNA [54]. Finally, ctDNA *RAS* wild-type patients experienced a significantly longer PFS if compared to ctDNA *RAS* mutated ctDNA (4.0 vs 1.9 months), while no

Table 1
Main characteristics of the published studies available in the literature and abstracts presented at international congresses with anti-EGFR retreatment in metastatic colorectal cancer (mCRC).

Study	Phase, prospective/ retrospective	Treatment strategy Drug time 1 -> Drug time 2 (Combination / Monotherapy)	Pts. (N)	Anatomic site (N)	RAS/BRAF	Tissue specimen Primary/Mets	Anti-EGFR free interval (months)	Outcome	RR%	SD%	DCR%
Rechallenge											
Santini, 2012	II, Prosp	Cmab -> Cmab (C)	39	Colon ns (19) Rectum or rectosigmoid (20)	KRAS cod 12–13 wt	nr	Median 6.0 (2.0–12.0)		53.8	35.9	89.7
Siravegna, 2015	Retrospect	Cmab -> Cmab (M) Cmab -> Pmab (M) Pmab -> Pmab (M)	3	nr	KRAS wt KAS wt KRAS wt (*)	Mets/ctDNA Mets/ctDNA Primary	10.4 6.3 29.5	PR SD PR			
Marks, 2015	II, Prosp	Cmab -> Cmab (C)	1	Rectum	KRAS, BRAF wt	Primary	6.5	SD			
Tsujii, 2016 (Abs.)	Retrospect	Cmab -> Cmab (C)	34	nr	KRAS wt	nr	nr	Median 7.7 (1.6–30.0)	2.9	53.0	55.9
Nogueira, 2016 (Abs.)	Retrospect	Cmab -> Cmab (C)	15	Colon ns (10) Rectum (5)	KRAS wt	nr	nr		13.3	26.7	40.0
Cremolini, 2018	II, Prosp	Cmab -> Cmab (C)	28	Right colon (9) Left colon or rectum (19)	RAS/ BRAF wt	nr/ctDNA (**)			21.4	32.1	53.5
Siena, 2017 (Abs.)	Retrospect	Pmab -> Pmab (C/M)	69	Right sided (8) Left sided (49) nr (12)	RAS wt, 2 BRAF mut	nr	nr	Median OS 14.2 months			
Tanioka, 2018	Retrospect	Cmab -> Cmab (C)	14	nr	KRAS ex 2 wt (12 allRAS wt, 2 RAS mut)	nr	Median 13.1 (6.0–37.1)		21.4	50.0	71.4
Tsujii, 2018 (Abs.)	II, Prosp	Pmab -> Pmab (C)	24	nr	KRAS wt	nr	nr		8.3	41.7	50.0
Osawa, 2018 (Abs.)	II, Prosp	Cmab -> Cmab (C)	33	Right colon (4) Left colon (29)	RAS wt	nr	> 4.0	Median PFS 2.9 / Median OS 8.7	15.6	40.6	56.2
Reintroduction											
Kaechele, 2008	Retrospect	Cmab -> Cmab (C) Cmab -> Cmab (C) Cmab -> Cmab (C) Cmab -> Cmab (C) Cmab -> Cmab (C)	5	Rectum or sigmoid colon (5)	nr	nr	13.0 14.1	PR SD			
Pietrantonio, 2013	Retrospect	Cmab -> Pmab (M)	30	nr	KRAS wt (**)	Prim/Mets (**)	32.0 13.3	PD PD			
Wasan, 2014 (*)	II, Prosp	Cmab -> Cmab (C)	78	Right or transvers colon (25) Left colon or rectum (55)	KRAS codons 12, 13, and 61 wt (**)	nr	Median 13.0 (8.0–39.0) Median 3.7 (3.5 – 4.6)	Median Median OS 16 months			
Sequence											
Ma, 2017	Prosp	Cmab -> Cmab (C)	1	Ascending colon	KRAS wt	nr	> 36.0	PR			
Metges, 2010 (Abs.)	Prosp	Cmab -> Pmab (M)	32	Rectum (12) Colon ns or double sites (20)	KRAS wt	nr			22.0	9.0	31.0
Wadlow, 2012	II, Prosp	Cmab -> Pmab (M)	20	nr	KRAS wt	nr			0.0	45.0	45.0
Kasagi, 2013	Retrospect	Cmab -> Pmab (M)	1	Rectum	KRAS, BRAF wt	Primary					
Marino, 2015	Retrospect	Cmab -> Pmab (M)	25 (*)	Rectum (9) Colon ns (16)	KRAS wt(ex 2 in 12 pts, ex 2–3 in 13 pts)	nr	nr	PR	4.0	20.0	24.0
Kiss, 2016	Retrospect	Cmab -> Pmab (M)	26 (*)	nr	KRAS wt	nr			11.5	26.9	38.4
Dose intensification											
Fora, 2013	II, Prosp	Cmab -> Cmab (C)	20	nr	KRAS wt (BRAF wt in 2/2 pts tested)	nr	nr		5.0	55.0	60.0
Mixed (readministration)											
Power, 2010	Retrospect	Cmab -> Pmab (C)	22	nr	KRAS cod 12–13 wt in 15 pts, mut in 3 pts, nr in 4 pts	nr	nr		41.0	14.0	55.0

(continued on next page)

Table 1 (continued)

Study	Phase, prospective/ retrospective	Treatment strategy Drug time 1 -> Drug time 2 (Combination / Monotherapy)	Pts. (N)	Anatomic site (N)	RAS/BRAF	Tissue specimen Primary/Mets	Anti-EGFR free interval (months)	Outcome	RR%	SD%	DCR%
Saif, 2010	Retrospect	Cmab -> Pmab (M)	15 (§)	nr	KRAS status evaluable in 3/15 pts: 1 wt, 2 mut	nr	nr		0.0	40.0	40.0
Naing, 2010		Cmab -> Cmab (C) Cmab -> Cmab (C) Pmab-Cmab -> Cmab (C) Cmab -> Cmab (C) Cmab -> Pmab (M/C)	4	nr nr nr Rectum Rectum (11) Colon (5)	nr nr nr nr KRAS wt in 13/16 pts, mut in 3/16 pts	nr nr nr nr nr	nr 11.0 / / 4.0 nr	SD SD SD SD			
Sonoda, 2013	Retrospect	Pmab -> Pmab (C) Pmab -> Pmab (C) Cmab / Pmab -> Cmab (C) / Pmab (C/M)	2 2 13	nr nr Rectum (5) Colon ns (§)	KRAS wt KRAS wt KRAS wt	Primary Primary nr	> 4.0 > 8.0 0.8 (0.2–10)	PR SD	0.0	54.0	54.0

Keys: M = monotherapy. C = combination therapy. Abs. = abstract. L = left. R = right. Nr = not reported. Ns = not specified.

(*) 1 case with KRAS amplification, 1 case KRAS wt at baseline, mut at first-line PD, wt at rechallenge.

(**) 3 KRAS mutations identified with mutant enriched PCR and not by standard Sanger sequencing (1 G13D, 1 G13S, 1 G12D): all three patients showed a partial response to previous cetuximab-based regimen but failed to respond to panitumumab at rechallenge (2 SD/1 PD).

(***) Tissue blocks were available before reintroduction for 21 patients treated with single agent Pmab and consenting for biomolecular analyses. Pretreatment samples were obtained from 14 (67%) primary tumors and 7 (33%) resected metastases.

(*) We reported data of the intermittent cetuximab arm.

(**) PAN-RAS and BRAF wt: 53 (68%), NRAS mutation 7 (9%), BRAF mutation 8 (10%).

(***) At treatment baseline patients were included in the study based on tissue RAS and BRAF wild-type assessment; ctDNA at rechallenge baseline enable the detection of RAS mutations in 12 out of 25 (48%).

(*) 20 out of 25 patients were evaluable for ORR.

(**) In 3 cases (11.5%) response was not evaluable.

(§) response to treatment evaluable only in 11 patients out of 15 due to deterioration of clinical conditions.

significant differences were observed in OS [54].

Reintroduction

Reintroduction strategy has been adopted in four studies in which the Authors stated that the reasons for first anti-EGFR including regimen interruption were other than PD [57–60]. The study by Pietrantonio and coworkers consisted in a reintroduction study with panitumumab monotherapy after a previous benefit from cetuximab based regimen in *KRAS* wild-type patients ($n = 30$) [58]. After a median of 13 months of anti-EGFR-free interval, the RR was 30%, SD 37% and DCR 67% [58]. No statistically significant correlation was found between the previous benefit from cetuximab and response to panitumumab [58]. Side effects or adverse events related to panitumumab reintroduction were not presented [58].

The COIN-B was a randomized phase 2 trial in which patients were assigned to intermittent FOLFOX plus intermittent cetuximab or to intermittent FOLFOX plus continuous cetuximab [60]. In both arms, the respective therapy was reintroduced after evidence of RECIST progression. Continuous cetuximab was associated with a greater failure-free survival (defined as stopping maximum tolerated treatment because of progression or death from any cause), greater PFS, and OS than was intermittent cetuximab, and with improved disease control at 24 weeks (32% vs 22%). However, the trial was not powered for statistical comparison between the treatment groups [60]. Kaechele and colleagues treated 5 patients with cetuximab-based regimen until disease stabilization. Then it was discontinued and reintroduced upon tumor progression with a clinical benefit in 3 patients [57]. A partial response to cetuximab reintroduction, after surgery and 3 years of therapy holiday, was reported by Ma and colleagues [59].

Sequence

In five publications, anti-EGFR retreatment with panitumumab monotherapy was started soon after a prior progression to cetuximab. Objective response rate adopting this strategy ranged between 0 and 22.0% and DCR 24%–45% [61–65]. All patients treated with this schedule had *RAS* wild-type tumors, but none of them were tested for EGFR external domain mutations, known to confer resistance to cetuximab but not to panitumumab [31,32]. Metges et al. firstly, in 2010, presented results of treatment of 32 patients with panitumumab monotherapy after progression to cetuximab associated with irinotecan. The RR and DCR were 20% and 31%, respectively. In the subgroup of patients that received clinical benefit from cetuximab and irinotecan, the RR to panitumumab was increased up to 54.5% with DCR of 72.7% (in case of cetuximab resistance, RR was 7.7% and DCR 15.4%) [61]. In contrast, Wadlow et al. found 0% of RR, a DCR of 45% with a median duration of 1.7 months in 20 patients treated with the same strategy [62].

More recently, Marino et al. and Kiss et al. retrospectively analyzed patients with *KRAS* wild-type mCRC who received panitumumab monotherapy after progression on cetuximab [64,65]. In the former study, 21 out of the 25 patients enrolled actually progressed on cetuximab (in 4 patients cetuximab was interrupted because of infusion reactions) and 20 patients were evaluable for -RR (5 died after 1–2 cycles of panitumumab). Among all patients included in the former, the RR was 4% and the DCR was 24% [64]. In the latter study, 26 patients were treated, RR was achieved in 11.5% with DCR of 38.4% (in 3 cases response was not available) [65].

Dose intensification

The phase II study by Fora and coworkers is the only one exploring this option of treatment. They tested the hypothesis of overcoming resistance to cetuximab in *KRAS* wild-type patients increasing its dosage up to 500 mg/m²/week together with irinotecan at standard dosage

[66]. Interestingly, the authors reported that patients enrolled in study later than 2 month from PD on standard doses of cetuximab experienced a significantly better PFS [66]. The study reported a good toxicity profile, obtaining a DCR up to 60% with a RR of 5% [66]. No significant difference in PFS with high doses of cetuximab was noted according to prior objective response to standard doses [66].

Mixed

In several studies, clinical criteria underlying anti-EGFR retreatment were not clearly established. In these reports, RR and DCR were comparable to studies in which anti-EGFR retreatment strategy had been clearly stated in the manuscript (RR: 4–41%; DCR: 24–55%). Power and colleagues showed the highest RR (41%) and DCR (55%), using panitumumab retreatment [67]. The majority of patients who responded to cetuximab continued to respond to panitumumab (8/9, 89%). Anti-EGFR free-interval was not reported but reasons for stopping cetuximab included hypersensitivity reactions (32%), disease progression (14%), convenience of bi-weekly schedule (23%), preceding surgery (18%), and no evidence of disease after resection of metastases (9%) [67]. Notably, this study was focused on the rates of cross hypersensitivity and infusion reactions between cetuximab and panitumumab, thereby only 14% of patients experienced PD during prior anti-EGFR therapy with cetuximab [67]. Saif et al. and Kajitani et al. reported a 0% of RR with DCR of 40% and 54%, respectively [68,70]. In the first study, all but one patient progressed on prior cetuximab therapy before to receive panitumumab monotherapy, *KRAS* status was mostly unknown and the interval between the two anti-EGFR therapy lines was not clearly reported [68]. In the second study, the prior chemotherapy with anti-EGFR antibody led to a partial response in four patients (31%), with 54% of stable disease. Patients who did not show clinical benefit from prior anti-EGFR antibody did not show evidence of clinical benefit from its readministration, with a median interval of 26 days [70]. Sonoda et al. reported a RR of 12.5% and a DCR of 43.8% from panitumumab retreatment (with or without chemotherapy) in patients that stopped prior cetuximab therapy principally for disease progression (81%). In the cohort of patients affected by *KRAS* wt mCRC (13/16), DCR was 53.8%. Anti-EGFR free interval was not reported [69].

Molecular assessment

Details of tissue specimen on which molecular assessment was performed have been reported in the minority of publications [26,51,58,63,71]. Three publications reported molecular assessment performed on primary tumor tissue [51,63,71], one clearly stated the percentage of assessment carried out on primary or metastatic tissue [58] and in one article assessment was performed on metastatic tissue and ctDNA [26]. Most of publications included patients with reported *KRAS* wild-type CRC, while only a few screened tumor specimen also for *BRAF* mutations [51,54]. Occasionally also patients harboring *KRAS* mutated CRC were included [58,67–69]. In only one study a dynamic evolution of *KRAS* alterations between first administration and rechallenge with anti-EGFR drugs was demonstrated by ctDNA [26]. Furthermore, in the CRICKET study *RAS* status in the ctDNA was retrospectively reported as predictive to identify patients more likely to obtain a PR to cetuximab rechallenge [54].

Toxicity

Data of grade 3 and 4 toxicity upon retreatment with anti-EGFR are reported in Table 2. The most frequent G3-4 toxicities were skin rashes and nail changes (5–38.5%) in studies using both anti-EGFR monotherapy or combination [48,50,54,60,64,66–68]. Neutropenia was reported in 8.3–40% of patients treated with combination of anti-EGFR and cytotoxic agents (mainly irinotecan) [48,49,52,54,57,60,66]. Other G3-4 toxicities reported were hypomagnesaemia (4–25%) and diarrhea

Table 2

Toxicities in patients undergoing anti-EGFR retreatment according to available peer-reviewed articles, abstracts and case reports included in the systematic review.

Study	Type of study <i>Prosp/retrosp (Phase)</i>	Treatment strategy <i>Drug time 1 - > drug time 2 (Combination / Monotherapy)</i>	Pts. N	Toxicities G3-4%	Type of toxicities
Rechallenge					
Santini, 2012	Prosp (II)	Cmab - > Cmab (C)	39	38.5	Skin rash
				7.7	Diarrhea
				18	Neutropenia
Siravegna, 2015	Retrosp	Cmab - > Cmab (M)	3	nr	nr
		Cmab - > Pmab (M)			
		Pmab - > Pmab (M)			
Marks, 2015		Cmab - > Pmab (C)	1	nr	nr
Tsuji, 2016 (Abs.)	Prosp (II)	Cmab - > Cmab (C)	34	28.6	Neutropenia
Nogueira, 2016 (Abs.)	Retrosp	Cmab - > Cmab (C)	15	13	Skin rash
Cremolini, 2018	Prosp (II)	Cmab - > Cmab (C)	28	18	Diarrhea
				14	Skin Toxicity
				14	Neutropenia
				7	Hand and foot syndrome
				4	Febrile neutropenia
				4	Stomatitis
				4	Nausea
				4	Conjunctivitis
				4	Hypomagnesemia
Siena, 2017 (Abs.)	Retrosp	Pmab - > Pmab (C/M)	69	nr	nr
Tanioka, 2018	Retrosp	Cmab - > Cmab (C)	13	7	Rash
				7	Diarrhea
Tsuji, 2018 (Abs.)	Prosp (II)	Pmab - > Pmab (C)	24	8.3	Neutropenia
Osawa, 2018 (Abs.)	II, Prosp	Cmab - > Cmab (C)	33	nr	nr
Reintroduction					
Pietrantonio, 2013	Retrosp	Cmab - > Pmab (M)	30	nr	nr
Kaechele, 2008		Cmab - > Cmab (C)	5	40	Neutropenia
		Cmab - > Cmab (C)		20	Skin rash and paronychia
		Cmab - > Cmab (C)		20	Diarrhea
		Cmab - > Cmab (C)			
		Cmab - > Cmab (C)			
Wasan, 2014	Prosp (II)	Cmab - > Cmab (C)	78	29	Neutropenia
				27	Skin rash
				26	Lethargy
				18	Diarrhea
				19	Pain
				12	Stomatitis
				11	Vomiting
				8	Nausea
				8	Anorexia
				8	Hand-Foot Syndrome
				5	Peripheral neurotoxicity
				4	Hypomagnesaemia
				4	Cetuximab-hypersensitivity
				3	Thrombocytopenia
Ma, 2017		Cmab - > Cmab (C)	1	0	-
Sequence					
Metges, 2010 (Abs.)	Prosp	Cmab - > Pmab (M)	32	nr	nr
Wadlow, 2012	Prosp (II)	Cmab - > Pmab (M)	20	5	Hyperglycemia
				5	Hyperbilirubinemia
				5	Hypokaliemia
Kasagi, 2013		Cmab - > Pmab (M)	1	nr	nr
Kiss, 2016	Retrosp	Cmab - > Pmab (M)	26	7.6	Skin rash
				3.8	Thrombosis
Dose intensification					
Fora, 2013	Prosp (II)	Cmab - > Cmab (C)	20	25	Hypomagnesemia
				10	Neutropenia
				5	Skin rash
				5	Diarrhea
				5	Hypokaliemia
				5	Nausea
				5	Fatigue
Mixed (readministration)					
Power, 2010	Retrosp	Cmab - > Pmab (C)	22	22	Skin rash
				14	Nail changes
				14	Diarrhea
				9	Hypomagnesemia
Saif, 2010	Retrosp	Cmab - > Pmab (M)	15	33.3	Skin rash
				6.6	Asthenia
Sonoda, 2013	Retrosp	Cmab - > Pmab (M/C)	16	6.3	Hypomagnesemia
				6.3	Hypocalcemia
Hata, 2013		Pmab - > Pmab (C)	2	0	-
		Pmab - > Pmab (C)			

(continued on next page)

Table 2 (continued)

Study	Type of study <i>Prosp/retrosp</i> (Phase)	Treatment strategy <i>Drug time 1 - > drug time 2 (Combination / Monotherapy)</i>	Pts. N	Toxicities G3-4%	Type of toxicities
Marino, 2015	Retrospect	Cmab - > Pmab (M)	25	32	Skin rash
Naing, 2010		Cmab - > Cmab (C)	4	nr	nr
		Cmab - > Cmab (C)			
		Pmab-Cmab - > Cmab (C)			
Kajitani 2017	Prosp	Cmab - > Cmab (C)	13	8	Thrombocytopenia
	Cmab/Pmab - > Cmab (C)/Pmab (C/M)	8		8	Paronychia
		8		8	Peripheral sensory neuropathy
		8		8	Ileitis

Keys: nr = not reported. N = number. G = grade. C = combination. M = monotherapy. Cmab = cetuximab. Pmab = Panitumumab. Prosp = prospective. Retrospect = retrospective. Abs = abstract.

(5–20%) [48,54,55,57,66,67,69]. In particular, hypomagnesemia was the most common G3-4 side effect in intensification dose strategy [66]. No toxic deaths have been reported. No correlation between response to anti-EGFR and toxicity has been statistically investigated in these studies likely due to the small number of patients in these studies.

Ongoing clinical trials

10 currently ongoing studies investigating efficacy and feasibility of anti-EGFR retreatment (Table 3) were found through ClinicalTrial.gov. These are all phase II trials except for FIRE-4 which is a phase III trial currently recruiting in Germany. Anti-EGFR monotherapy is used in 5 out of 10 studies (CHRONOS, RASINTRO, PACER, NCT03524820, and NCT03087071). Two studies are based on dynamic of changes of RAS mutated clones assessed by ctDNA by liquid biopsy (CHRONOS and RASINTRO) (Fig. 3).

Discussion

Anti-EGFR retreatment in mCRC has been empirically investigated in a limited number of mainly retrospective studies soon after the introduction of cetuximab and panitumumab in clinical practice. However, the underlying molecular bases of this therapeutic option have been recently demonstrated and clinicians are increasingly focused towards its optimization in the context of the *continuum of care*. To this aim, we adopted a categorization of the clinical use of retreatment into four classes (rechallenge, reintroduction, sequence and dose intensification) to overcome heterogeneity of available studies and compare different strategies. However, in most articles criteria driving anti-EGFR retreatment strategy were ambiguous, hampering a clear generalizable categorization for clinical use and making difficult to derive definite conclusions to translate in the clinical practice.

In most of the studies, information about intervening treatments and length of intervals between first anti-EGFR treatment and retreatment were missing. However, the role of an intervening treatment is paramount in this setting, especially since its length can impact the re-establishing of anti-EGFR drugs sensitivity [26,35]. Experimental and clinical data suggest that RAS and EGFR mutant clones exponentially decay [26], with a cumulative half-life of 4.3 months in patients [35]. Therefore, the time interval between first exposure and retreatment with an anti-EGFR should be taken into account for evaluating potential (in)success at rechallenge. This has not been demonstrated when adopting retreatment strategies different from rechallenge, providing the latter with the strongest potential for selection of patients before readministration of anti-EGFR drugs. Ongoing trials such as CHRONOS (Fig. 3) and RASINTRO (Table 3) are evaluating patients with longitudinal liquid biopsy and could provide prospective data concerning optimal biologically driven timing for rechallenge. In addition to rechallenge, also sequence with anti-EGFR drugs has an underlying molecular rationale, as there are acquired mutations occurring in the

extracellular domain of EGFR under selective pressure of cetuximab (i.e. S492R) leading to resistance to cetuximab but not to panitumumab [31,32]. However, sequence-strategic studies considered in this review did not screen patients for these alterations [61–65]. Finally, dose intensification strategies have also been demonstrated to have a pre-clinical biological rationale [39,40]. Overall, it is fundamental to consider timing between first use and retreatment and type of drug sequencing (cetuximab and then panitumumab or viceversa, or the same drugs given as retreatment) to reconcile clinical use of retreatment with the underlying biological mechanisms and make results more generalizable and successful.

A major limitations in the majority of studies reviewed is that the molecular status of KRAS was assessed retrospectively on archival tissue [50,53,58,64–66]. In addition, another limitation is that in some studies also KRAS mutant CRC patients were included [67–69]. It is well known that tumor heterogeneity can increase along different lines of metastatic treatments [26,72–74], making molecular information retrieved from archival tissue analysis potentially outdated. Furthermore, selection exerted by therapy continuously reshape individual lesions. Molecular characterization of mCRC can also take place by liquid biopsy for ctDNA detection at the actual moment of retreatment [26,54,75,76], and application of this technique for driving anti-EGFR retreatment is warranted and will likely impact on this therapeutic strategy. Moreover, it should be noted that tumor sidedness was reported only in some of the studies evaluated in present review [48,50,51,53,54,57,59,63,64,69,70]. As expected based on data showing that a different underlying genetic make-up ultimately lead to better results of anti-EGFR drugs in left-sided tumors [77,78], most of study considered in this review were enriched of tumors arising in this side of the colon [48,53,54,57,60]. However, efficacy of anti-EGFR retreatment has been reported also in right sided CRC [59] and conclusive comparisons are not available even if it would be reasonable to expect a greater benefit of anti-EGFR retreatment in left sided rather than in right sided CRC, similarly to first line treatment [77,78]. Finally, another limitation of performing a systemic review on these trials is that data of efficacy have mostly reported as objective response rate rather than survival data. OS was stated in only one retrospective publication and one prospective phase II study [53,60].

We found that toxicities given by readministration of anti-EGFR drugs were generally reported as mild, and the most common severe G3-4 adverse events were skin rashes, paronychia and hypomagnesaemia when given as monotherapy and in addition neutropenia and diarrhea when associated with other cytotoxic agents, usually irinotecan [48,49,54,57,60,66]. These effects probably favorably compare with those experienced by patients after rechallenge with cytotoxic agents such as oxaliplatin that might be worse and even lethal [79,80]. Nevertheless, these assumptions should be confirmed by clinical trials comparing efficacy as well as safety of the different third-line treatment options such as the FIRE-4 AIO-KRK-0114 (NCT02934529) clinical trial testing anti-EGFR rechallenge as third line option of

Table 3
Ongoing studies investigating activity of anti-EGFR antibodies retreatment in metastatic colorectal cancer.

Study (study ID) STATUS Phase Main location	Anti-EGFR agent or combination in rechallenge setting	Main inclusion criteria
A-REPEAT (NCT03311750) RECRUITING Phase II Trial Greek	Panitumumab + CT	<ul style="list-style-type: none"> ● RAS wt on tumor tissue ● Clinical benefit from 1st line regimen including anti-EGFR drugs ● Second line intervening treatments without anti-EGFR
REGAIN (NCT02316496) TERMINATED Phase II Trial France	Cetuximab + irinotecan	<ul style="list-style-type: none"> ● RAS and BRAF wt on tumor tissue ● First line chemotherapy regimen with FOLFIRI + cetuximab with initial PR/CR and PD with PD > 6 weeks after the last administration of cetuximab.
FIRE-4 (NCT02934529) AIO-KRK-0114 RECRUITING Phase III Trial Germany	Cetuximab + CT vs CT in third line	<ul style="list-style-type: none"> ● RAS wt on tumor tissue ● First-line FOLFIRI + cetuximab therapy producing at least PR or SD lasting ≥ 6 months.
CHRONOS (NCT03227926) RECRUITING Phase II Trial Italy	Panitumumab monotherapy	<ul style="list-style-type: none"> ● RAS and BRAF wt on tumor tissue at baseline ● First line anti-EGFR therapy producing at least PR ● Defined criteria of RAS mutational load measurement by liquid biopsy during first line treatment and before rechallenge ● > 50% drop in RAS-extended mutational load between BML and RML (Fig. 3)
(NCT01832467) ACTIVE NOT RECRUITING Phase II Trial Hong Kong	Cetuximab + CT	<ul style="list-style-type: none"> ● Retreatment with cetuximab-based chemotherapy in patients upon PD while under observation, defined as radiological or clinical PD more than 60 days from the last day of administration ● Previously responded to first-line or second-line treatment with cetuximab-based chemotherapy.
RASINTRO (NCT03259009) NOT RECRUITING YET Phase II Trial France	Cetuximab/Panitumumab monotherapy	<ul style="list-style-type: none"> ● Previous anti-EGFR based chemotherapy having provided an OR ● No longer mutated RAS clone in plasma that appeared during PD with the first anti-EGFR treatment.
PACER (NCT01801904) ACTIVE NOT RECRUITING Phase II Trial Italy	Panitumumab monotherapy in patients cetuximab-refractory	<ul style="list-style-type: none"> ● Documented PD following a treatment with cetuximab in patients who showed an OR after 8 weeks or SD after 16 weeks
(NCT03087071) RECRUITING Phase II Trial USA	Panitumumab monotherapy	<ul style="list-style-type: none"> ● Previous treatment with cetuximab with evidence of clinical benefit ● Ultimate PD through previous treatment with cetuximab with documented PD ● Must not have EGFR ectodomain mutation or any mutations in KRAS, NRAS, or BRAF in ctDNA
(NCT03524820) RECRUITING Phase II Trial Israel	Cetuximab monotherapy	<ul style="list-style-type: none"> ● RAS WT on tumor tissue ● At least three months progression free time in first line cetuximab treatment. ● Monitoring liquid biopsy during rechallenge but it is not a liquid biopsy driven study
OPTIPRIME (NCT03584711) RECRUITING Phase II Trial France	Panitumumab + FOLFOX	<ul style="list-style-type: none"> ● RAS WT on tumor tissue ● Reintroduction “Stop and go” strategy ● No prior chemotherapy as first line treatment for metastatic disease and adjuvant chemotherapy discontinued for more than 12 months

treatment in RAS wild-type patients.

Overall, the emerging message of this review is that the benefit from anti-EGFR retreatment seems maximized when anti-EGFR drug are used in the rechallenge setting rather than other strategies [48,54]. However, all the studies, because of their retrospective nature or, if prospective phase II trials, for the low number of patients included, are not robust enough to drive clinical decision making and therefore conclusions obtained from our systematic review should be taken with caution. Further perspective trials, especially if based on monitoring of actual genetic make-up of resistance derived by ctDNA, comparing anti-EGFR retreatment with standard treatments in the third- or later line settings are warranted to affirm the role of this strategy in the *continuum of care* of mCRC.

Author agreement/declaration

All authors have approved the final article. The article is the

authors' original work, hasn't received prior publication and isn't under consideration for publication elsewhere.

Contributors

- Gianluca Mauri: conception and design of the review, acquisition, analysis and interpretation of data, drafting of the article.
- Elio Gregory Pizzutilo: conception and design of the review, acquisition, analysis and interpretation of data, drafting of the article.
- Alessio Amatu: acquisition and interpretation of data, critical revision of the draft.
- Katia Bencardino: analysis and interpretation of data, critical revision of the draft.
- Laura Palmeri: acquisition and interpretation of data, critical revision of the draft.
- Erica Francesca Bonazzina: acquisition and interpretation of data, critical revision of the draft.




Fig. 3. The 3-steps selection strategy of the CHRONOS Trial (see also Table 3).

- Federica Tosi: acquisition and interpretation of data, critical revision of the draft.
- Giulia Carlo-Stella: analysis and interpretation of data, critical revision of the draft.
- Giovanni Burrafato: analysis and interpretation of data, critical revision of the draft.
- Francesco Scaglione: interpretation of data, critical revision of the draft.
- Silvia Marsoni: interpretation of data, critical revision of the draft.
- Giulia Siravegna: interpretation of data, critical revision of the draft.
- Alberto Bardelli: analysis and interpretation of data, critical revision of the draft.
- Salvatore Siena: conception and design of the review, analysis and interpretation of data, critical revision of the draft, final approval of the version to be submitted.
- Andrea Sartore-Bianchi: conception and design of the review, analysis and interpretation of data, drafting of the article, critical revision of the draft, final approval of the version to be submitted.

Acknowledgement

Authors are supported by grants from Associazione Italiana Ricerca Cancro grant AIRC 5 x mille [Project ID 51000] Special Program Molecular Clinical Oncology, AIRC Investigator Grant [Project ID 20685 and 16788], and AIRC Special Program 5 per mille metastases [Project ID 21091]; CODIS Community Research and Development Information Service, Horizon 2020 [Project ID 635342] grant Molecularly Guided Trials with Specific Treatment Strategies in Patients with Advanced Newly Molecular Defined Subtypes of Colorectal Cancer (MoTriColor); Fondazione Oncologia Niguarda Onlus, grant Terapia Molecolare dei Tumori and grant Studies to Develop Therapies Against Colorectal Cancer in Young Adults.

Funding

No one for this paper.

Declaration of interests

A.S.-B. has acted as a consultant/advisory member for Amgen, Bayer, Lilly and Merck-Serono. S.S. is advisory board member for Amgen, Bayer, BMS, Celgene, Incyte, Merck, Novartis, Roche, Seattle Genetics. A.B. has acted as a consultant/advisory member for Horizon Discovery, Biocartis and Trovogene. A.A. is advisory board member for Amgen and Bayer.

References

- [1] Ferlay J, Soerjomataram I, Dikshit R, Eser S, Mathers C, Rebelo M, et al. Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012. *Int J Cancer* 2015;136:E359–86. <https://doi.org/10.1002/ijc.29210>.
- [2] Siegel RL, Miller KD, Fedewa SA, Ahnen DJ, Meester RGS, Barzi A, et al. Colorectal cancer statistics, 2017. *CA Cancer J Clin* 2017;67:177–93. <https://doi.org/10.3322/caac.21395>.
- [3] Van Cutsem E, Cervantes A, Nordlinger B, Arnold D. ESMO Guidelines Working Group. Metastatic colorectal cancer: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. *Ann Oncol Off J Eur Soc Med Oncol* 2014;25(Suppl 3):iii1–9. <https://doi.org/10.1093/annonc/mdu260>.
- [4] Venook AP, Niedzwiecki D, Lenz H-J, Innocenti F, Fruth B, Meyerhardt JA, et al. Effect of first-line chemotherapy combined with cetuximab or bevacizumab on overall survival in patients with KRAS wild-type advanced or metastatic colorectal cancer: a randomized clinical trial. *JAMA* 2017;317:2392–401. <https://doi.org/10.1001/jama.2017.7105>.
- [5] Loupakis F, Cremolini C, Masi G, Lonardi S, Zagonel V, Salvatore L, et al. Initial therapy with FOLFIRI and bevacizumab for metastatic colorectal cancer. *N Engl J Med* 2014;371:1609–18. <https://doi.org/10.1056/NEJMoa1403108>.
- [6] Douillard J-Y, Oliner KS, Siena S, Tabernero J, Burkes R, Barugel M, et al. Panitumumab-FOLFOX4 treatment and RAS mutations in colorectal cancer. *N Engl J Med* 2013;369:1023–34. <https://doi.org/10.1056/NEJMoa1305275>.
- [7] Ciardiello F, Normanno N, Maiello E, Martinelli E, Troiani T, Pisconti S, et al. Clinical activity of FOLFIRI plus cetuximab according to extended gene mutation status by next-generation sequencing: findings from the CAPRI-GOIM trial. *Ann Oncol Off J Eur Soc Med Oncol* 2014;25:1756–61. <https://doi.org/10.1093/annonc/mdu230>.
- [8] Van Cutsem E, Cervantes A, Adam R, Sobrero A, Van Krieken JH, Aderka D, et al. ESMO consensus guidelines for the management of patients with metastatic colorectal cancer. *Ann Oncol Off J Eur Soc Med Oncol* 2016;27:1386–422. <https://doi.org/10.1093/annonc/mdw235>.
- [9] Benson AB, Venook AP, Al-Hawary MM, Cederquist L, Chen Y-J, Ciombor KK, et al. NCCN guidelines insights: colon cancer, version 2.2018. *J Natl Compr Cancer Netw JNCCN* 2018;16:359–69. <https://doi.org/10.6004/jnccn.2018.0021>.

- [10] Arnold D, Prager GW, Quintela A, Stein A, Moreno Vera S, Mounedji N, et al. Beyond second-line therapy in patients with metastatic colorectal cancer: a systematic review. *Ann Oncol Off J Eur Soc Med Oncol* 2018;29:835–56. <https://doi.org/10.1093/annonc/ndy038>.
- [11] Grothey A, Van Cutsem E, Sobrero A, Siena S, Falcone A, Ychou M, et al. Regorafenib monotherapy for previously treated metastatic colorectal cancer (CORRECT): an international, multicentre, randomised, placebo-controlled, phase 3 trial. *Lancet Lond Engl* 2013;381:303–12. [https://doi.org/10.1016/S0140-6736\(12\)61900-X](https://doi.org/10.1016/S0140-6736(12)61900-X).
- [12] Mayer RJ, Van Cutsem E, Falcone A, Yoshino T, Garcia-Carbonero R, Mizunuma N, et al. Randomized trial of TAS-102 for refractory metastatic colorectal cancer. *N Engl J Med* 2015;372:1909–19. <https://doi.org/10.1056/NEJMoa1414325>.
- [13] Cunningham D, Humblet Y, Siena S, Khayat D, Bleiberg H, Santoro A, et al. Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer. *N Engl J Med* 2004;351:337–45. <https://doi.org/10.1056/NEJMoa033025>.
- [14] Hecht JR, Patnaik A, Berlin J, Venook A, Malik I, Tchekmedyan S, et al. Panitumumab monotherapy in patients with previously treated metastatic colorectal cancer. *Cancer* 2007;110:980–8. <https://doi.org/10.1002/cncr.22915>.
- [15] Lièvre A, Bachet J-B, Le Corre D, Boige V, Landi B, Emile J-F, et al. KRAS mutation status is predictive of response to cetuximab therapy in colorectal cancer. *Cancer Res* 2006;66:3992–5. <https://doi.org/10.1158/0008-5472.CAN-06-0191>.
- [16] Benvenuti S, Sartore-Bianchi A, Di Nicolantonio F, Zanoni C, Moroni M, Veronese S, et al. Oncogenic activation of the RAS/RAF signaling pathway impairs the response of metastatic colorectal cancers to anti-epidermal growth factor receptor antibody therapies. *Cancer Res* 2007;67:2643–8. <https://doi.org/10.1158/0008-5472.CAN-06-4158>.
- [17] Sorich MJ, Wiese MD, Rowland A, Kichenadasse G, McKinnon RA, Karapetis CS. Extended RAS mutations and anti-EGFR monoclonal antibody survival benefit in metastatic colorectal cancer: a meta-analysis of randomized, controlled trials. *Ann Oncol Off J Eur Soc Med Oncol* 2015;26:13–21. <https://doi.org/10.1093/annonc/mdl378>.
- [18] Peeters M, Kafatos G, Taylor A, Gastanaga VM, Oliner KS, Hechmati G, et al. Prevalence of RAS mutations and individual variation patterns among patients with metastatic colorectal cancer: A pooled analysis of randomised controlled trials. *Eur J Cancer Oxf Engl* 1990;2015(51):1704–13. <https://doi.org/10.1016/j.ejca.2015.05.017>.
- [19] Yang Z-Y, Wu X-Y, Huang Y-F, Di M-Y, Zheng D-Y, Chen J-Z, et al. Promising biomarkers for predicting the outcomes of patients with KRAS wild-type metastatic colorectal cancer treated with anti-epidermal growth factor receptor monoclonal antibodies: a systematic review with meta-analysis. *Int J Cancer* 2013;133:1914–25. <https://doi.org/10.1002/ijc.28153>.
- [20] Di Nicolantonio F, Martini M, Molinari F, Sartore-Bianchi A, Arena S, Saletti P, et al. Wild-type BRAF is required for response to panitumumab or cetuximab in metastatic colorectal cancer. *J Clin Oncol Off J Am Soc Clin Oncol* 2008;26:5705–12. <https://doi.org/10.1200/JCO.2008.18.0786>.
- [21] Sartore-Bianchi A, Martini M, Molinari F, Veronese S, Nichelatti M, Artale S, et al. PIK3CA mutations in colorectal cancer are associated with clinical resistance to EGFR-targeted monoclonal antibodies. *Cancer Res* 2009;69:1851–7. <https://doi.org/10.1158/0008-5472.CAN-08-2466>.
- [22] Bokemeyer C, Van Cutsem E, Rougier P, Ciardiello F, Heeger S, Schlichting M, et al. Addition of cetuximab to chemotherapy as first-line treatment for KRAS wild-type metastatic colorectal cancer: pooled analysis of the CRYSTAL and OPUS randomised clinical trials. *Eur J Cancer Oxf Engl* 1990;2012(48):1466–75. <https://doi.org/10.1016/j.ejca.2012.02.057>.
- [23] Moroni M, Veronese S, Benvenuti S, Marrapese G, Sartore-Bianchi A, Di Nicolantonio F, et al. Gene copy number for epidermal growth factor receptor (EGFR) and clinical response to anti-EGFR treatment in colorectal cancer: a cohort study. *Lancet Oncol* 2005;6:279–86. [https://doi.org/10.1016/S1470-2045\(05\)70102-9](https://doi.org/10.1016/S1470-2045(05)70102-9).
- [24] Bertotti A, Papp E, Jones S, Adleff V, Anagnostou V, Lupo B, et al. The genomic landscape of response to EGFR blockade in colorectal cancer. *Nature* 2015;526:263–7. <https://doi.org/10.1038/nature14969>.
- [25] Medico E, Russo M, Picco G, Cancelliere C, Valtorta E, Corti G, et al. The molecular landscape of colorectal cancer cell lines unveils clinically actionable kinase targets. *Nat Commun* 2015;6:7002. <https://doi.org/10.1038/ncomms8002>.
- [26] Siravegna G, Mussolin B, Buscarino M, Corti G, Cassingena A, Crisafulli G, et al. Clonal evolution and resistance to EGFR blockade in the blood of colorectal cancer patients. *Nat Med* 2015;21:827. <https://doi.org/10.1038/nm0715-827b>.
- [27] Cremolini C, Morano F, Moretto R, Berenato R, Tamborini E, Perrone F, et al. Negative hyper-selection of metastatic colorectal cancer patients for anti-EGFR monoclonal antibodies: the PRESSING case-control study. *Ann Oncol Off J Eur Soc Med Oncol* 2017;28:3009–14. <https://doi.org/10.1093/annonc/mdx546>.
- [28] Misale S, Yaeger R, Hobor S, Scala E, Janakiramam M, Liska D, et al. Emergence of KRAS mutations and acquired resistance to anti-EGFR therapy in colorectal cancer. *Nature* 2012;486:532–6. <https://doi.org/10.1038/nature11156>.
- [29] Diaz LA, Williams RT, Wu J, Kinzie I, Hecht JR, Berlin J, et al. The molecular evolution of acquired resistance to targeted EGFR blockade in colorectal cancers. *Nature* 2012;486:537–40. <https://doi.org/10.1038/nature11219>.
- [30] Bardelli A, Corso S, Bertotti A, Hobor S, Valtorta E, Siravegna G, et al. Amplification of the MET receptor drives resistance to anti-EGFR therapies in colorectal cancer. *Cancer Discov* 2013;3:658–73. <https://doi.org/10.1158/2159-8290.CD-12-0558>.
- [31] Montagut C, Dalmases A, Bellosillo B, Crespo M, Pairet S, Iglesias M, et al. Identification of a mutation in the extracellular domain of the Epidermal Growth Factor Receptor conferring cetuximab resistance in colorectal cancer. *Nat Med* 2012;18:221–3. <https://doi.org/10.1038/nm.2609>.
- [32] Arena S, Bellosillo B, Siravegna G, Martínez A, Cañadas I, Lazzari L, et al. Emergence of multiple EGFR extracellular mutations during cetuximab treatment in colorectal cancer. *Clin Cancer Res Off J Am Assoc Cancer Res* 2015;21:2157–66. <https://doi.org/10.1158/1078-0432.CCR-14-2821>.
- [33] Montagut C, Argilés G, Ciardiello F, Poulsen TT, Dienstmann R, Kragh M, et al. Efficacy of Sym004 in patients with metastatic colorectal cancer with acquired resistance to anti-EGFR therapy and molecularly selected by circulating tumor DNA analyses: A phase 2 randomized clinical trial. e175245 *JAMA Oncol* 2018;4. <https://doi.org/10.1001/jamaoncol.2017.5245>.
- [34] Siravegna G, Marsoni S, Siena S, Bardelli A. Integrating liquid biopsies into the management of cancer. *Nat Rev Clin Oncol* 2017;14:531–48. <https://doi.org/10.1038/nrclinonc.2017.14>.
- [35] Parseghian CM, Loree JM, Morris VK, Lima Pereira AA, Sanchez EV, Kee BK, et al. Anti-EGFR resistant clones decay exponentially after progression: Implications for anti-EGFR rechallenge. *J Clin Oncol* 2018;36. suppl; abstract 3511.
- [36] Tonini G, Imperatori M, Vincenzi B, Frezza AM, Santini D. Rechallenge therapy and treatment holiday: different strategies in management of metastatic colorectal cancer. *J Exp Clin Cancer Res CR* 2013;32:92. <https://doi.org/10.1186/1756-9966-32-92>.
- [37] Kuczyński EA, Sargent DJ, Grothey A, Kerbel RS. Drug rechallenge and treatment beyond progression—implications for drug resistance. *Nat Rev Clin Oncol* 2013;10:571–87. <https://doi.org/10.1038/nrclinonc.2013.158>.
- [38] Maindral-Gobelo F, Tournigand C, André T, Carola E, Mabro M, Artru P, et al. Oxaliplatin reintroduction in patients previously treated with leucovorin, fluorouracil and oxaliplatin for metastatic colorectal cancer. *Ann Oncol Off J Eur Soc Med Oncol* 2004;15:1210–4. <https://doi.org/10.1093/annonc/mdh305>.
- [39] Azzopardi N, Lecomte T, Ternant D, Boisdron-Celle M, Piller F, Morel A, et al. Cetuximab pharmacokinetics influences progression-free survival of metastatic colorectal cancer patients. *Clin Cancer Res Off J Am Assoc Cancer Res* 2011;17:6329–37. <https://doi.org/10.1158/1078-0432.CCR-11-1081>.
- [40] Van Cutsem E, Tejpar S, Vanbeckvoort D, Peeters M, Humblet Y, Gelderblom H, et al. Inpatient cetuximab dose escalation in metastatic colorectal cancer according to the grade of early skin reactions: the randomized EVEREST study. *J Clin Oncol Off J Am Soc Clin Oncol* 2012;30:2861–8. <https://doi.org/10.1200/JCO.2011.40.9243>.
- [41] Moher D, Liberati A, Tetzlaff J, Altman DG, PRISMA Group. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. *J Clin Epidemiol* 2009;62:1006–12. <https://doi.org/10.1016/j.jclinepi.2009.06.005>.
- [42] Liberati A, Altman DG, Tetzlaff J, Mulrow C, Gøtzsche PC, Ioannidis JPA, et al. The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: explanation and elaboration. *e1000100 PLoS Med* 2009;6. <https://doi.org/10.1371/journal.pmed.1000100>.
- [43] Sartore-Bianchi A, Siena S, Tonini G, Bardelli A, Santini D. Overcoming dynamic molecular heterogeneity in metastatic colorectal cancer: Multikinase inhibition with regorafenib and the case of rechallenge with anti-EGFR. *Cancer Treat Rev* 2016;51:54–62. <https://doi.org/10.1016/j.ctrv.2016.10.006>.
- [44] Nielsen DL, Palshof JA, Larsen FO, Jensen BV, Pfeiffer P. A systematic review of salvage therapy to patients with metastatic colorectal cancer previously treated with fluorouracil, oxaliplatin and irinotecan +/- targeted therapy. *Cancer Treat Rev* 2014;40:701–15. <https://doi.org/10.1016/j.ctrv.2014.02.006>.
- [45] Goldberg RM, Montagut C, Wainberg ZA, Ronga P, Audhuf F, Taieb J, et al. Optimising the use of cetuximab in the continuum of care for patients with metastatic colorectal cancer. e000353 *ESMO Open* 2018;3. <https://doi.org/10.1136/esmoopen-2018-000353>.
- [46] Foubert F, Matysiak-Budnik T, Toucheff Y. Options for metastatic colorectal cancer beyond the second line of treatment. *Dig Liver Dis Off J Ital Soc Gastroenterol Ital Assoc Study Liver* 2014;46:105–12. <https://doi.org/10.1016/j.dld.2013.07.002>.
- [47] Liu X, George GC, Tsimberidou AM, Naing A, Wheler JJ, Kopetz S, et al. Retreatment with anti-EGFR based therapies in metastatic colorectal cancer: impact of intervening time interval and prior anti-EGFR response. *BMC Cancer* 2015;15:713. <https://doi.org/10.1186/s12885-015-1701-3>.
- [48] Santini D, Vincenzi B, Addeo R, Garufi C, Masi G, Scartozzi M, et al. Cetuximab rechallenge in metastatic colorectal cancer patients: how to come away from acquired resistance? *Ann Oncol Off J Eur Soc Med Oncol* 2012;23:2313–8. <https://doi.org/10.1093/annonc/mdr623>.
- [49] Tsuji A, Eto T, Masuishi T, Satake H, Segawa Y, Tanioka H, et al. Phase II study of third-line cetuximab rechallenge in patients with metastatic wild-type K-RAS colorectal cancer who achieved a clinical benefit in response to first-line cetuximab plus chemotherapy (JACCRO CC-08). *Ann Oncol* 2016;27. <https://doi.org/10.1093/annonc/mdw370.58>.
- [50] Nogueira A, Rodrigues J, Jacinto P, Ribeiro J, Bonito N, Marques M, et al. P-167Cetuximab rechallenge in metastatic colorectal cancer patients. *Ann Oncol* 2016;27:ii49-ii50. <https://doi.org/10.1093/annonc/mdw199.161>.
- [51] Marks E, Rizvi SM, Sarwani N, Yang Z, El-Deiry WS. A case of heterogeneous sensitivity to panitumumab in cetuximab-refractory colorectal adenocarcinoma metastases. *Cancer Biol Ther* 2015;16:377–82. <https://doi.org/10.1080/15384047.2015.1004927>.
- [52] Tsuji A, Nakamura M, Watanabe T, Manaka D, Matsuoka H, Kataoka M, et al. P-243Phase II study of third-line panitumumab rechallenge in patients with metastatic wild-type KRAS colorectal cancer who achieved a clinical benefit in response to first-line panitumumab plus chemotherapy. *Ann Oncol* 2018;29. <https://doi.org/10.1093/annonc/mdl151.242>.
- [53] Siena S, George P, Gerald P, Andrea S-B, Aziz Z, Jean-Yves D, et al. Rechallenge with EGFR inhibitors in patients with metastatic colorectal cancer: effect on outcomes. *Ann Oncol* 2017;28. <https://doi.org/10.1093/annonc/mdx261.317>.

- [54] Cremolini C, Rossini D, Dell'Aquila E, Lonardi S, Conca E, Del Re M, et al. Rechallenge for patients With RAS and BRAF wild-type metastatic colorectal cancer with acquired resistance to first-line cetuximab and irinotecan: a phase 2 single-arm clinical trial. *JAMA Oncol* 2018. <https://doi.org/10.1001/jamaoncol.2018.5080>.
- [55] Tanioka H, Asano M, Yoshida R, Waki N, Uno F, Ishizaki M, et al. Cetuximab re-treatment in patients with metastatic colorectal cancer who exhibited a clinical benefit in response to prior cetuximab: A retrospective study. *Oncol Lett* 2018;16:3674–80. <https://doi.org/10.3892/ol.2018.9127>.
- [56] Osawa H, Shinozaki E, Nakamura M, Ohhara Y, Shindo Y, Shiozawa M, et al. 481PPhase II study of cetuximab rechallenge in patients with ras wild-type metastatic colorectal cancer: E-rechallenge trial. *Ann Oncol* 2018;29. <https://doi.org/10.1093/annonc/mdy281.029>.
- [57] Kaechele V, von Wichert G, Adler G, Seufferlein T. Response to reintroduction of cetuximab in 5 patients with advanced, chemotherapy-resistant, colorectal cancer without progressive disease following first-line therapy with a cetuximab-containing regimen. *Oncology* 2008;74:123–6. <https://doi.org/10.1159/000151358>.
- [58] Pietrantonio F, Perrone F, Biondani P, Maggi C, Lampis A, Bertan C, et al. Single agent panitumumab in KRAS wild-type metastatic colorectal cancer patients following cetuximab-based regimens: Clinical outcome and biomarkers of efficacy. *Cancer Biol Ther* 2013;14:1098–103. <https://doi.org/10.4161/cbt.26343>.
- [59] Ma J, Yang Q-L, Ling Y. Rechallenge and maintenance therapy using cetuximab and chemotherapy administered to a patient with metastatic colorectal cancer. *BMC Cancer* 2017;17:132. <https://doi.org/10.1186/s12885-017-3133-8>.
- [60] Wasan H, Meade AM, Adams R, Wilson R, Pugh C, Fisher D, et al. Intermittent chemotherapy plus either intermittent or continuous cetuximab for first-line treatment of patients with KRAS wild-type advanced colorectal cancer (COIN-B): a randomised phase 2 trial. *Lancet Oncol* 2014;15:631–9. [https://doi.org/10.1016/S1470-2045\(14\)70106-8](https://doi.org/10.1016/S1470-2045(14)70106-8).
- [61] Metges J, Raoul J, Achour N, Capitain O, Gourlaouen A, Ramée J, et al. PANERB study: Panitumumab after cetuximab-based regimen failure. *J Clin Oncol* 2010;28:e14000. https://doi.org/10.1200/jco.2010.28.15_suppl.e14000.
- [62] Wadlow RC, Hezel AF, Abrams TA, Blaszkowsky LS, Fuchs CS, Kulke MH, et al. Panitumumab in patients with KRAS wild-type colorectal cancer after progression on cetuximab. *Oncologist* 2012;17:14. <https://doi.org/10.1634/theoncologist.2011-0452>.
- [63] Kasagi Y, Oki E, Ando K, Kimura Y, Ikegami T, Saeki H, et al. A case of panitumumab-responsive metastatic rectal cancer initially refractory to cetuximab. *Case Rep Oncol* 2013;6:382–6. <https://doi.org/10.1159/000353781>.
- [64] Marino A, Caliollo C, Sponziello F, Nacci A, Quaranta A, Mazzoni E, et al. Panitumumab after progression on cetuximab in KRAS wild-type metastatic colorectal cancer patients: a single institution experience. *Tumori* 2015;101:524–8. <https://doi.org/10.5301/tj.5000356>.
- [65] Kiss I, Mlcochova J, Bortlicek Z, Poprach A, Drabek J, Vychytilova-Faltejskova P, et al. Efficacy and toxicity of panitumumab after progression on cetuximab and predictive value of MiR-31-5p in metastatic wild-type KRAS colorectal cancer patients. *Anticancer Res* 2016;36:4955–9. <https://doi.org/10.21873/anticancer.11063>.
- [66] Fora AA, McMahon JA, Wilding G, Groman A, Ma WW, Romano KS, et al. A phase II study of high-dose cetuximab plus irinotecan in colorectal cancer patients with KRAS wild-type tumors who progressed after standard dose of cetuximab plus irinotecan. *Oncology* 2013;84:210–3. <https://doi.org/10.1159/000346328>.
- [67] Power DG, Shah MA, Asmis TR, Garcia JJ, Kemeny NE. Safety and efficacy of panitumumab following cetuximab: retrospective review of the Memorial Sloan-Kettering experience. *Invest New Drugs* 2010;28:353–60. <https://doi.org/10.1007/s10637-009-9268-y>.
- [68] Saif MW, Kaley K, Chu E, Copur MS. Safety and efficacy of panitumumab therapy after progression with cetuximab: experience at two institutions. *Clin Colorectal Cancer* 2010;9:315–8. <https://doi.org/10.3816/CCC.2010.n.046>.
- [69] Sonoda H, Mekata E, Shimizu T, Endo Y, Tani T. Safety and efficacy of panitumumab therapy after metastatic colorectal cancer progression with cetuximab: Experience at a single Japanese institution. *Oncol Lett* 2013;5:1331–4. <https://doi.org/10.3892/ol.2013.1171>.
- [70] Kajitani T, Makiyama A, Arita S, Shimokawa H, Oda H, Shirakawa T, et al. Anti-epidermal growth factor receptor antibody readministration in chemorefractory metastatic colorectal cancer. *Anticancer Res* 2017;37:6459–68. <https://doi.org/10.21873/anticancer.12101>.
- [71] Hata A, Katakami N, Fujita S, Takatori K, Horai A, Kitajima N, et al. Panitumumab rechallenge in chemorefractory patients with metastatic colorectal cancer. *J Gastrointest Cancer* 2013;44:456–9. <https://doi.org/10.1007/s12029-012-9453-7>.
- [72] Siena S, Sartore-Bianchi A, Garcia-Carbonero R, Karthaus M, Smith D, Tabernero J, et al. Dynamic molecular analysis and clinical correlates of tumor evolution within a phase II trial of panitumumab-based therapy in metastatic colorectal cancer. *Ann Oncol Off J Eur Soc Med Oncol* 2018;29:119–26. <https://doi.org/10.1093/annonc/mdx504>.
- [73] Siravegna G, Lazzari L, Crisafulli G, Sartore-Bianchi A, Mussolin B, Cassingena A, et al. Radiologic and genomic evolution of individual metastases during HER2 blockade in colorectal cancer. *e7 Cancer Cell* 2018;34(148–162). <https://doi.org/10.1016/j.ccell.2018.06.004>.
- [74] Caswell DR, Swanton C. The role of tumour heterogeneity and clonal cooperativity in metastasis, immune evasion and clinical outcome. *BMC Med* 2017;15:133. <https://doi.org/10.1186/s12916-017-0900-y>.
- [75] Diehl F, Schmidt K, Choti MA, Romans K, Goodman S, Li M, et al. Circulating mutant DNA to assess tumor dynamics. *Nat Med* 2008;14:985–90. <https://doi.org/10.1038/nm.1789>.
- [76] Diehl F, Li M, Dressman D, He Y, Shen D, Szabo S, et al. Detection and quantification of mutations in the plasma of patients with colorectal tumors. *Proc Natl Acad Sci U S A* 2005;102:16368–73. <https://doi.org/10.1073/pnas.0507904102>.
- [77] Boeckx N, Koukakis R, Op de Beeck K, Rolfo C, Van Camp G, Siena S, et al. Primary tumor sidedness has an impact on prognosis and treatment outcome in metastatic colorectal cancer: results from two randomized first-line panitumumab studies. *Ann Oncol Off J Eur Soc Med Oncol* 2017;28:1862–8. <https://doi.org/10.1093/annonc/mdx119>.
- [78] Ciombor KK, Goldberg RM. Primary tumor sidedness as prognostic and predictive biomarker in metastatic colorectal cancer: further validation of a potentially practice-changing variable. *JAMA Oncol* 2016. <https://doi.org/10.1001/jamaoncol.2016.3777>.
- [79] Bencardino K, Mauri G, Amatu A, Tosi F, Bonazzina E, Palmeri L, et al. Oxaliplatin immune-induced syndrome occurs with cumulative administration and rechallenge: single institution series and systematic review study. *Clin Colorectal Cancer* 2016;15:213–21. <https://doi.org/10.1016/j.clcc.2016.02.001>.
- [80] Mauri G, Bencardino K, Sartore-Bianchi A, Siena S. Toxicity of oxaliplatin rechallenge in metastatic colorectal cancer. *Ann Oncol Off J Eur Soc Med Oncol* 2018. <https://doi.org/10.1093/annonc/mdy306>.